StreetInsider.com News Articles

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

Bayer today announced that new investigational data from KERENDIA’s Phase III clinical trial program will be presented in scientific sessions at the 63rd European Renal Association (ERA) Congress taking place June 3-6, 2026, in Glasgow, Scotland. Presentations include:

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Barclays on Bayer AG (BAYN:GR) (BAYRY): 'Conditional transfer of settlement to federal level adds noise'

Tue, 02 Jun 2026 05:16:13 -0400

Barclays analyst James Gordon reiterated an Overweight rating and EUR50.00 price target on Bayer AG (BAYN:GR) (OTC: BAYRY).

The analyst comments "JPML’s conditional transfer raises timing and headline risk to BAYN proposed settlement, but with jurisdiction of this move in question, we see limited fundamental impact. Opt-out deadline remains 4 Jun; incremental delays to 9 July decision possible. Expect shares to underperform. BAYN's proposed $7.25bn Roundup settlement now faces another procedural hurdle, having been granted conditional transfer to the federal level by the Judicial Panel for Multidistrict Litigation (JPML), which could potentially combine the settlement with the recent MDL that was

Barclays on Bayer AG (BAYN:GR) (BAYRY): 'Conditional transfer of settlement to federal level adds noise'

Tue, 02 Jun 2026 05:16:13 -0400

Barclays analyst James Gordon reiterated an Overweight rating and EUR50.00 price target on Bayer AG (BAYN:GR) (OTC: BAYRY).

Barclays on Bayer AG (BAYN:GR) (BAYRY): 'Conditional transfer of settlement to federal level adds noise'

Tue, 02 Jun 2026 05:16:13 -0400

Barclays analyst James Gordon reiterated an Overweight rating and EUR50.00 price target on Bayer AG (BAYN:GR) (OTC: BAYRY).